BIO-TECHNE Corp — Form 8-K
Filed August 12, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 92/100
What the filing says
On June 25, 2026, Bio-Techne agreed to be acquired by Merck KGaA, Darmstadt, Germany for $73 per share in cash, representing a total enterprise value of approximately $11.3 billion. The transaction was announced during the company's Q4 FY2026 earnings (ended June 30, 2026), in which Bio-Techne reported flat full-year revenue of $1.2 billion, GAAP EPS of $1.16 (vs. $0.46 prior year), and adjusted EPS of $1.93 (flat vs. $1.92 prior year). Bio-Techne has ceased holding investor conference calls due to the pending transaction.
Why this rating
Acquisition at full enterprise value ($11.3B) equals 99% of public market cap ($11.4B)—company ceases to exist as independent entity. Business-changing for shareholders and employees; extremely material event.
See more from August 12, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.